Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Toxicology Letters|October 12, 2010
Distribution of melamine in rat foetuses and neonatesC Y Chu, K O Chu, Judy Y W Chan, et al.
Lung Cancer (Amsterdam, Netherlands)|May 1, 2021
Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapySally C M Lau, Christopher Poletes, Lisa W Le, et al.
Journal of Orthopaedic Translation|January 13, 2021
Satisfactory long-term survival, functional and radiological outcomes of open-wedge high tibial osteotomy for managing knee osteoarthritis: Minimum 10-year follow-up studyLawrence C M Lau, Jason C H Fan, Kwong-Yin Chung, et al.
Therapeutic Advances in Medical Oncology|October 30, 2025
A retrospective analysis exploring the association of pretreatment neutrophil-to-lymphocyte ratio and immune checkpoint inhibitor outcomes in patients with advanced NSCLC and liver metastasesMaisam Makarem, Tuan Hoang, Mitchell J Elliott, et al.
Clinical Lung Cancer|February 14, 2021
Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint InhibitorsSally C M Lau, Aline Fusco Fares, Lisa W Le, et al.
Diabetes, Obesity & Metabolism|June 16, 2026
Type 2 Diabetes Is Associated With Increased Complications and Mortality After Hip Fracture in Older Adults Aged 60 Years or OlderXincheng Zou, Manju Chandran, Xi Xiong, et al.
JTO Clinical and Research Reports|September 25, 2023
Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential TherapiesSally C M Lau, Kirstin Perdrizet, Andrea S Fung, et al.
Cancer|January 29, 2025
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancerJacob M Sands, Stéphane Champiat, Horst-Dieter Hummel, et al.
JTO Clinical and Research Reports|December 17, 2021
Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and EfficacySally C M Lau, Malcolm Ryan, Jessica Weiss, et al.
Lung Cancer (Auckland, N.Z.)|June 28, 2024
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus SurveySai-Hong Ignatius Ou, Xiuning Le, Misako Nagasaka, et al.
Pageof 7